| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
6 Integrin,
6p1
Department of Radiation Oncology, Arizona Cancer Center [T. L. D., F. B., A. E. C.], and the Department of Molecular and Cellular Biology [A. E. C.], University of Arizona, Tucson, Arizona 85724-5024
We have reported previously the existence of an Mr 70,000 form of the
6 integrin called
6p in a variety of human epithelial cell lines. Four different experimental conditions were used to examine the regulation of
6 and
6p integrin. The production of the
6 integrin was decreased by 45% using a protein translation inhibitor (2.25 µM puromycin), whereas production of the
6p variant was unaffected. The
6p variant was decreased 60% by actin depolymerization (10 µM cytochalasin D) corresponding to a decrease in its surface expression, whereas
6 integrin production was unaffected. The
6p variant was resistant to endoglycosidase H treatment, whereas the
6 integrin was both sensitive and resistant to endoglycosidase H treatment, indicating retention in the endoplasmic reticulum and processing through the Golgi apparatus. Additionally, digestion by endoglycosidase F demonstrated both
6p and
6 integrin contained NH2-linked glycosylations and both shifted Mr
10,000 on enzymatic digestion. Finally, inhibition of serine/threonine phosphatases by either calyculin A (15 nM) or okadaic acid (62 µM) did not affect
6p, whereas the production of
6 integrin was decreased by 50%. These data suggest that the production of the
6p variant is distinct from
6 integrin and may involve a post-translational processing event at the cell surface.
This article has been cited by other articles:
![]() |
J. Liu, P. B. Gurpur, and S. J. Kaufman Genetically Determined Proteolytic Cleavage Modulates {alpha}7{beta}1 Integrin Function J. Biol. Chem., December 19, 2008; 283(51): 35668 - 35678. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |